At the same time, intratumoral heterogeneity is a well-known feature of breast cancer that is associated with therapeutic and diagnostic implications, especially in the context of immunohistochemical evaluation of hormone receptors, Ki67 and HER2 (15). Here, ERBB2 is linked to breast carcinoma.